
Page#1
Consolidated Statements of Operations
For the Years Ended December 31,
In millions, except per share amounts 2019 2018 2017
Revenues: 
Products $ 185,236 $ 183,910 $ 180,063
Premiums 63,122 8,184 3,558
Services 7,407 1,825 1,144
Net investment income 1,011 660 21
Total revenues 256,776 194,579 184,786
Operating costs:
Cost of products sold 158,719 156,447 153,448
Benefit costs 52,529 6,594 2,810
Goodwill impairments — 6,149 181
Operating expenses 33,541 21,368 18,809
Total operating costs 244,789 190,558 175,248
Operating income 11,987 4,021 9,538
Interest expense 3,035 2,619 1,062
Loss on early extinguishment of debt 79 — —
Other expense (income) (124) (4) 208
Income before income tax provision 8,997 1,406 8,268
Income tax provision 2,366 2,002 1,637
Income (loss) from continuing operations 6,631 (596) 6,631
Loss from discontinued operations, net of tax — — (8)
Net income (loss) 6,631 (596) 6,623
Net (income) loss attributable to noncontrolling interests 3 2 (1)
Net income (loss) attributable to CVS Health $ 6,634 $ (594) $ 6,622
Basic earnings (loss) per share:
Income (loss) from continuing operations attributable to CVS Health $ 5.10 $ (0.57) $ 6.48
Loss from discontinued operations attributable to CVS Health $ — $ — $ (0.01)
Net income (loss) attributable to CVS Health $ 5.10 $ (0.57) $ 6.47
Weighted average basic shares outstanding 1,301 1,044 1,020
Diluted earnings (loss) per share:
Income (loss) from continuing operations attributable to CVS Health $ 5.08 $ (0.57) $ 6.45
Loss from discontinued operations attributable to CVS Health $ — $ — $ (0.01)
Net income (loss) attributable to CVS Health $ 5.08 $ (0.57) $ 6.44
Weighted average diluted shares outstanding 1,305 1,044 1,024
Dividends declared per share $ 2.00 $ 2.00 $ 2.00
See accompanying notes to consolidated financial statements.
91
Page#2
Consolidated Statements of Comprehensive Income (Loss)
For the Years Ended December 31,
In millions 2019 2018 2017
Net income (loss) $ 6,631 $ (596) $ 6,623
Other comprehensive income (loss), net of tax:
Net unrealized investment gains 677 97 —
Foreign currency translation adjustments 162 (29) (2)
Net cash flow hedges (33) 330 (10)
Pension and other postretirement benefits 111 (124) 152
Other comprehensive income 917 274 140
Comprehensive income (loss) 7,548 (322) 6,763
Comprehensive (income) loss attributable to noncontrolling interests 3 2 (1)
Comprehensive income (loss) attributable to CVS Health $ 7,551 $ (320) $ 6,762
See accompanying notes to consolidated financial statements.
92
Page#3
Consolidated Balance Sheets
At December 31,
In millions, except per share amounts 2019 2018
Assets: 
Cash and cash equivalents $ 5,683 $ 4,059
Investments 2,373 2,522
Accounts receivable, net 19,617 17,631
Inventories 17,516 16,450
Other current assets 5,113 4,581
Total current assets 50,302 45,243
Long-term investments 17,314 15,732
Property and equipment, net 12,044 11,349
Operating lease right-of-use assets 20,860 —
Goodwill 79,749 78,678
Intangible assets, net 33,121 36,524
Separate accounts assets 4,459 3,884
Other assets 4,600 5,046
Total assets $ 222,449 $ 196,456
Liabilities:
Accounts payable $ 10,492 $ 8,925
Pharmacy claims and discounts payable 13,601 11,365
Health care costs payable 6,879 6,147
Policyholders’ funds 2,991 2,939
Accrued expenses 12,133 10,711
Other insurance liabilities 1,830 1,937
Current portion of operating lease liabilities 1,596 —
Short-term debt — 720
Current portion of long-term debt 3,781 1,265
Total current liabilities 53,303 44,009
Long-term operating lease liabilities 18,926 —
Long-term debt 64,699 71,444
Deferred income taxes 7,294 7,677
Separate accounts liabilities 4,459 3,884
Other long-term insurance liabilities 7,436 8,119
Other long-term liabilities 2,162 2,780
Total liabilities 158,279 137,913
Commitments and contingencies (Note 16)
Shareholders’ equity:
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —
Common stock, par value $0.01: 3,200 shares authorized; 1,727 shares issued and 1,302
shares outstanding at December 31, 2019 and 1,720 shares issued and 1,295 shares
outstanding at December 31, 2018 and capital surplus 45,972 45,440
Treasury stock, at cost: 425 shares at both December 31, 2019 and 2018 (28,235) (28,228)
Retained earnings 45,108 40,911
Accumulated other comprehensive income 1,019 102
Total CVS Health shareholders’ equity 63,864 58,225
Noncontrolling interests 306 318
Total shareholders’ equity 64,170 58,543
Total liabilities and shareholders’ equity $ 222,449 $ 196,456
See accompanying notes to consolidated financial statements.
93
Page#4
Consolidated Statements of Cash Flows
For the Years Ended December 31,
In millions 2019 2018 2017
Cash flows from operating activities:  
Cash receipts from customers $ 248,393 $ 186,519 $ 176,594
Cash paid for inventory and prescriptions dispensed by retail network
pharmacies (149,655) (148,981) (146,469)
Insurance benefits paid (52,242) (6,897) (2,810)
Cash paid to other suppliers and employees (28,932) (17,234) (15,348)
Interest and investment income received 955 644 21
Interest paid (2,954) (2,803) (1,072)
Income taxes paid (2,717) (2,383) (2,909)
Net cash provided by operating activities 12,848 8,865 8,007
Cash flows from investing activities:
Proceeds from sales and maturities of investments 7,049 817 61
Purchases of investments (7,534) (692) (137)
Purchases of property and equipment (2,457) (2,037) (1,918)
Proceeds from sale-leaseback transactions 5 — 265
Acquisitions (net of cash acquired) (444) (42,226) (1,181)
Proceeds from sale of subsidiary and other assets — 832 —
Other 42 21 33
Net cash used in investing activities (3,339) (43,285) (2,877)
Cash flows from financing activities:
Net repayments of short-term debt (720) (556) (598)
Proceeds from issuance of long-term debt 3,736 44,343 —
Repayments of long-term debt (8,336) (5,522) —
Derivative settlements (25) 446 —
Repurchase of common stock — — (4,361)
Dividends paid (2,603) (2,038) (2,049)
Proceeds from exercise of stock options 210 242 329
Payments for taxes related to net share settlement of equity awards (112) (97) (71)
Other — 1 (1)
Net cash provided by (used in) financing activities (7,850) 36,819 (6,751)
Effect of exchange rate changes on cash, cash equivalents and restricted cash — (4) 1
Net increase (decrease) in cash, cash equivalents and restricted cash 1,659 2,395 (1,620)
Cash, cash equivalents and restricted cash at the beginning of the period 4,295 1,900 3,520
Cash, cash equivalents and restricted cash at the end of the period $ 5,954 $ 4,295 $ 1,900
94
Page#5
For the Years Ended December 31,
In millions 2019 2018 2017
Reconciliation of net income (loss) to net cash provided by operating activities:
Net income (loss) $ 6,631 $ (596) $ 6,623
Adjustments required to reconcile net income (loss) to net cash provided by
operating activities:
Depreciation and amortization 4,371 2,718 2,479
Goodwill impairments — 6,149 181
Loss on settlement of defined benefit pension plans — — 187
Stock-based compensation 453 280 234
Loss on sale of subsidiary 205 86 —
Loss on early extinguishment of debt 79 — —
Deferred income taxes (654) 87 (1,334)
Other noncash items 264 253 53
Change in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable, net (2,158) (1,139) (941)
Inventories (1,075) (1,153) (514)
Other assets (614) (3) (338)
Accounts payable and pharmacy claims and discounts payable 3,550 2,329 1,710
Health care costs payable and other insurance liabilities 320 (311) —
Other liabilities 1,476 165 (333)
Net cash provided by operating activities $ 12,848 $ 8,865 $ 8,007
See accompanying notes to consolidated financial statements.
95
Page#6
Consolidated Statements of Shareholders’ Equity
Attributable to CVS Health
Number of shares Common Accumulated Total
outstanding Stock and Other CVS Health Total 
Capital Comprehensive Shareholders’ Shareholders’
Common Treasury Treasury Retained Noncontrolling 
(2)
In millions (1) Surplus (1) Income (Loss) Equity Equity
Shares Shares Stock Earnings Interests 
Balance at December
31, 2016 1,705 (644) $ 31,635 $ (33,483) $ 38,983 $ (305) $ 36,830 $ 4 $ 36,834
Net income — — — — 6,622 — 6,622 1 6,623
Other comprehensive
income (Note 13) — — — — — 140 140 — 140
Stock option activity,
stock awards and other 7 — 461 — — — 461 — 461
Purchase of treasury
shares, net of ESPP
— (54) — (4,313) — — (4,313) — (4,313)
issuances
Common stock dividends — — — — (2,049) — (2,049) — (2,049)
Other decreases in
noncontrolling interests — — — — — — — (1) (1)
Balance at December
31, 2017 1,712 (698) 32,096 (37,796) 43,556 (165) 37,691 4 37,695
Adoption of new 
(3)
accounting standards — — — — (6) (7) (13) — (13)
Net loss — — — — (594) — (594) (2) (596)
Other comprehensive
income (Note 13) — — — — — 274 274 — 274
Common shares issued to
acquire Aetna — 274 12,923 9,561 — — 22,484 — 22,484
Stock option activity,
stock awards and other 8 — 421 — — — 421 — 421
Purchase of treasury
shares, net of ESPP
— (1) — 7 — — 7 — 7
issuances
Common stock dividends — — — — (2,045) — (2,045) — (2,045)
Acquisition of
noncontrolling interests — — — — — — — 329 329
Other decreases in
noncontrolling interests — — — — — — — (13) (13)
Balance at December
31, 2018 1,720 (425) 45,440 (28,228) 40,911 102 58,225 318 58,543
Adoption of new
accounting standards
(Note 1) — — — — 178 — 178 — 178
Net income (loss) — — — — 6,634 — 6,634 (3) 6,631
Other comprehensive
income (Note 13) — — — — — 917 917 — 917
Stock option activity,
stock awards and other 7 2 532 — — — 532 — 532
Purchase of treasury
shares, net of ESPP
— (2) — (7) — — (7) — (7)
issuances
Common stock dividends — — — — (2,615) — (2,615) — (2,615)
Other decreases in
noncontrolling interests — — — — — — — (9) (9)
Balance at December
31, 2019 1,727 (425) $ 45,972 $ (28,235) $ 45,108 $ 1,019 $ 63,864 $ 306 $ 64,170
_____________________________________________
(1) Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2019, 2018 and 2017. Treasury stock includes $29 million 
related to shares held in trust for each of the years ended December 31, 2019 and 2018 and $31 million related to shares held in trust for the year ended 
December 31, 2017. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.
(2) Common stock and capital surplus includes the par value of common stock of $17 million as of December 31, 2019, 2018 and 2017.
(3) Reflects the adoption of Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which resulted in a reduction to retained 
earnings of $13 million and the adoption of ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain 
Tax Effects from Accumulated Other Comprehensive Income, which resulted in a reduction to accumulated other comprehensive income of $7 million and 
an increase to retained earnings of $7 million, each during the year ended December 31, 2018.
See accompanying notes to consolidated financial statements.
96